Valbiotis gains over 4% in Paris as Oddo BHF maintains its 'outperform' rating on the stock, with a price target raised from 10 to 11.5 euros.

As a reminder, earlier this week Valbiotis published its Phase II/III clinical results for TOTUM-63 in pre-diabetes. These proved positive, demonstrating a statistically significant reduction in fasting glycemia in patients vs. placebo.

According to Oddo BHF, given its health nutrition status, TOTUM-63 is already scheduled to be marketed in 2024, in collaboration with Nestlé Health Science.

'So we now see the clinical and regulatory aspects secured. Given its profile, Valbiotis combines the opportunities of a biotech company with a lower development risk, which makes it more attractive", concludes the broker.


Copyright (c) 2023 CercleFinance.com. All rights reserved.